CEROW
Income statement / Annual
Last year (2023), CERo Therapeutics Holdings, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, CERo Therapeutics Holdings, Inc.'s net income was -$2,536.23.
See CERo Therapeutics Holdings, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
| Research and Development
Expenses |
$0.00
|
$9.85 M
|
$9.14 M
|
| General & Administrative
Expenses |
$2,892.94
|
$2.13 M
|
$2.48 M
|
| Selling & Marketing
Expenses |
$2.89 M
|
$715,763.00
|
-$2.23 M
|
| Selling, General &
Administrative Expenses |
$2.89 M
|
$2.84 M
|
$251,705.00
|
| Other Expenses |
$40,050.00 |
-$64,050.00 |
-$80,320.00 |
| Operating Expenses |
$2.93 M |
$2.91 M |
$332,026.00 |
| Cost And Expenses |
$2.93 M |
$2.91 M |
$332,030.00 |
| Interest Income |
$491,571.00 |
$142,115.00 |
$986,711.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$2,932.99
|
$1.07 M
|
$735,473.00
|
| EBITDA |
-$2.44 M
|
-$68,577.00
|
-$332,030.00
|
| EBITDA Ratio |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$491,571.00
|
$2.84 M
|
$99,081.00
|
| Income Before Tax |
-$2.44 M |
-$68,577.00 |
-$332,415.00 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
| Income Tax Expense |
$94,819.00 |
$599,159.00 |
-$16,868.00 |
| Net Income |
-$2,536.23 |
-$667,736.00 |
-$315,547.00 |
| Net Income Ratio |
0 |
0 |
0 |
| EPS |
-0.39 |
-0.0986 |
-0.0137 |
| EPS Diluted |
-0.39 |
-0.0986 |
-0.0137 |
| Weighted Average Shares
Out |
$6.53 M
|
$6.77 M
|
$22.98 M
|
| Weighted Average Shares
Out Diluted |
$6.53 M
|
$6.77 M
|
$22.98 M
|
| Link |
|
|
|
